NCT01863147View on ClinicalTrials.gov

Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Newly Diagnosed Type 2 DiabetesCoronary Artery Disease
Interventions
DRUG

Sitagliptin and acarbose

Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.

Trial Locations (2)

430070

Guangda Xiang, Wuhan

Wuhan General Hospital, Wuhan

All Listed Sponsors
lead

Wuhan General Hospital of Guangzhou Military Command

OTHER

NCT01863147 - Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease | Biotech Hunter | Biotech Hunter